BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:05 PM
 | 
Feb 25, 2010
 |  BC Extra  |  Company News

NICE backs Cimzia, Yondelis

The U.K.'s NICE issued final guidance for two drugs: Cimzia certolizumab pegol from UCB Group (Euronext:UCB) and Yondelis trabectedin from PharmaMar S.A. (Madrid, Spain). NICE recommended the use...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >